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Abstract: The risk of cardiovascular diseases and type 2 diabetes mellitus are increased in subjects
with metabolic syndrome (MetS), and hydrolyzed fish protein may have favorable effects on metabolic
health. Here, we investigated the effect of 8 weeks supplementation with 4 g of cod protein hydrolysate
(CPH) on glucose metabolism, lipid profile and body composition in individuals with MetS in a
double-blind, randomized intervention study with a parallel-group design. Subjects received a
daily supplement of CPH (n = 15) or placebo (n = 15). Primary outcomes were serum fasting
and postprandial glucose levels. Secondary outcomes were fasting and postprandial insulin and
glucagon-like peptide 1 (GLP-1), fasting lipid concentrations and body composition. No difference
was observed between CPH and placebo for insulin, glucose or GLP-1 after 8 weeks intervention.
Fasting triacylglycerol decreased in both the CPH group and placebo group, with no change between
groups. Fasting total cholesterol and low-density lipoprotein cholesterol decreased significantly
within both groups from baseline to study end, but no difference was observed between the two groups.
In conclusion, supplementing with a low dose of CPH in subjects with MetS for 8 weeks had no effect
on fasting or postprandial levels of insulin, glucose or GLP-1, lipid profile or body composition.
Keywords: metabolic syndrome; cod protein hydrolysate; glucose metabolism; lipid
metabolism; obesity
1. Introduction
Hyperglycemia, hypertension, dyslipidemia and abdominal obesity form a cluster of
interconnected metabolic abnormalities commonly known as the metabolic syndrome (MetS), which
increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) [1–3].
The prevalence of MetS varies depending on the definition used and the population studied, but it
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is estimated that between 20 and 30% of the adult population in most countries meet the diagnostic
criteria for MetS [4]. Currently, the first-line therapy for MetS is education on lifestyle changes including
physical activity and weight reduction, and improvement of risk factors closely linked to MetS [3].
The syndrome has significant negative impact on public health, and the rate of MetS is expected to
continue to rise in adults and future generations unless we find effective strategies to prevent and
reverse this development [4]. It is of interest to find ways to prevent and alleviate MetS, beyond the
currently used strategies.
Based on associations seen between fish consumption and increased levels of high-density
lipoprotein cholesterol (HDL-C) and reduced levels of triacylglycerols (TAG), increased consumption
of fish may improve metabolic health and prevent development of MetS [5–8]. The nutrients in fish,
such as iodine, vitamin D, taurine, long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) and
high-quality protein, may all contribute to the positive health effects of fish consumption [9]. There
is also emerging evidence that proteins from fish contain bioactive peptides and may potentially
modulate physiological processes in the human body, and contribute with a number of effects beyond
their nutritional value as a source of energy and amino acids [10,11]. Bioactive peptides are released
naturally by gastric digestion, produced by fermentation in the gut or through hydrolyzed protein
added to the diet [12]. Animal and human studies suggest that hydrolyzed fish proteins given in low
doses may have beneficial effects on lipid metabolism [13–15], postprandial glucose [14] and insulin
regulation [16], as well as body composition and appetite [17,18]. Similar indications are observed in
intervention studies with healthy overweight and obese adults given low doses (between 2.5 and 8 g)
of supplements with unhydrolyzed cod protein [19–21].
We have previously investigated supplementation with low doses of a cod protein hydrolysate
(CPH) on glucose metabolism and appetite in healthy adults [16,22], as well as supplementation for
6 weeks on inflammation and gastrointestinal health in patients with irritable bowel syndrome [23].
It is of interest to further evaluate the possible effects of low doses of CPH in a group of participants
with metabolic abnormalities, such as subjects with MetS, over a longer period. Therefore, we aimed
to investigate whether supplementation with low doses of 4 g of CPH per day for 8 weeks would
have an effect on postprandial glucose metabolism and the appetite hormone glucagon-like peptide 1
(GLP-1), lipid profile and body composition in subjects with MetS. We hypothesized that the small
peptides present in the CPH supplement would serve as rapidly absorbed bioactive peptides and lead
to beneficial changes in glucose metabolism and an overall healthier metabolic profile.
2. Materials and Methods
2.1. Study Design
This study was as a multicenter, double-blinded, randomized, intervention with a parallel-group
design. Participants with MetS received a daily supplement of 4 g of CPH (active ingredient) or placebo
(no active ingredient) for 8 weeks. The primary outcome was fasting and postprandial glucose levels.
Secondary outcomes were other metabolic and clinical parameters of the metabolic syndrome (waist
circumference, fasting TAG and HDL-C), as well as fasting and postprandial insulin and GLP-1 levels,
total cholesterol (total-C), fasting low-density lipoprotein cholesterol (LDL-C), and body composition.
All subjects gave their written informed consent for inclusion before participation in this study.
This study was conducted in accordance with the Declaration of Helsinki and all procedures involving
human subjects were approved by the Regional Committee for Medical and Health Research Ethics of
Central Norway (2018/2163). This study is registered at clinicaltrials.gov (NCT03807752).
2.2. Participants and Study Setting
Between March and September 2019, we recruited participants to this study through advertisement
on the internal and external websites, on notice boards at Haukeland University Hospital (HUH), Bergen,
and Ålesund Hospital, Ålesund, and at general practitioners in Bergen and the surrounding area.
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The criteria for inclusion were age between 40 and 70 years, body mass index (BMI) between 27
and 35 kg/m2 and the presence of MetS. Criteria for exclusion were chronic diseases or medication that
were likely to interfere with the evaluation of the study endpoints (e.g., T2DM, medications known to
affect glucose and lipid metabolism), allergy or intolerance to fish and/or shellfish, excessive alcohol
consumption and/or drug as assessed by physician, acute infections or unwillingness to comply with
the study requirements. As blood pressure was not an outcome measure, we allowed participants
using certain types of blood pressure medications, not known to clinically affect glucose metabolism,
to take part in this study. This included diuretics, calcium-channel blockers and agents acting on the
renin-angiotensin system. Participants using beta-blocking agents or peripheral vasodilators were
excluded. Four weeks prior to starting the intervention and during this study, the participants had to
stop using any nutritional supplements with n-3 PUFAs. No changes in food consumption or level of
physical activity were allowed. Lastly, the participants had to remain at a stable weight for the last
three months and not be involved in any weight-loss programs prior to or during the intervention.
2.3. Definition of Metabolic Syndrome
The Joint Interim Statement was used to define MetS, in which the presence of any three of five risk
factors qualifies for a diagnosis of MetS: elevated fasting glucose, s-TAG, reduced HDL-C, increased
waist circumference (WC) or elevated blood pressure [1]. Furthermore, we used the International
Diabetes Federation cut-off points for central obesity (WC ≥ 80 cm in women; ≥94 cm in men) [24].
The cut-off points for the other components were as follows: s-glucose ≥ 5.5 mmol/L, s-TAG ≥
1.7 mmol/L, s-HDL-C < 1.0 mmol/L in men and <1.3 mmol/L in women, systolic blood pressure ≥
130 mmHg and/or diastolic blood pressure ≥ 85 mmHg [1].
2.4. Study Visits
All possible participants responding through the online recruitment form were pre-screened by
telephone. Based on this, we invited potential participants to a screening visit to evaluate the presence
of MetS and eligibility in terms of inclusion and exclusion criteria. The screening visit included a
clinical examination by a physician, a review of medical history, vital sign (blood pressure, heart rate),
anthropometric measures (weight, height and waist circumference) and blood sampling. We measured
height and weight to the nearest 0.1 cm or 0.1 kg using an electronic weight/height scale and used these
parameters to calculate BMI (kg/m2). Furthermore, at screening and end of study visit, we measured
waist circumference (WC) according to WHO recommendations [25,26], i.e., locating the midpoint
between the lower margin of the last palpable rib and the top of iliac crest, with arms relaxed at the side,
at the end of a normal expiration and using a stretch-resistant measuring tape with constant tension.
On days of study visits, the participants came to the study center in the morning. After an
overnight fast (i.e., after 9:00 pm the previous day, the participants could not eat/drink or use nicotine),
all study procedures were performed. Fasting blood samples were taken, and anthropometric measures
were performed. Body composition was measured by a bioelectrical impedance analysis (BIA) device
at baseline and end of study visit (Body Composition Analyzer, BC-418 MA (model used in Ålesund),
MC-180 MA (model used in Bergen), Tanita Corporation, Tokyo, Japan), following the manufacturers’
guidelines—barefoot with light clothing and an empty bladder.
Following the baseline measurement, the participants consumed a standardized breakfast meal
(test meal). It consisted of two slices of semi-coarse bread (80 g bread, 50% whole wheat), 20 g
white cheese, 25 g strawberry jam, 10 g margarine and 1.5 dL orange juice, providing a total of
1840 kJ (440 kcal), 69 g carbohydrate, 13.3 g protein and 14.3 g fat. We calculated the energy and
macronutrient content using “Kostholdsplanleggeren” (Norwegian Food Safety Authority and The
Norwegian Directorate of Health, Oslo, Norway) [27]. The participants consumed the meal within
15 min. Blood was drawn from an antecubital vein in the fasting state (−20 min), at 0 min, i.e.,
immediately after the meal was finished, and thereafter at 20, 40, 60, 80, 100 and 120 min. To induce an
Nutrients 2020, 12, 1991 4 of 15
adequate blood glucose response, we calculated the required amount of energy and macronutrient in
the test meal. We allowed free drinking of water, but did not serve coffee or tea.
The participants started the intervention on the day following the baseline visit. They opened the
sealed bag with powder (active or placebo) and mixed well with 100 mL cold water. The participants
consumed the supplement 10 min before breakfast every day for 8 weeks, except for the morning of
the end of study visit due to required fast.
2.5. Test Material
Firmenich Bjørge Biomarin AS (Ålesund, Norway) manufactured the test material. The flavored
white powder came pre-packed in cardboard boxes from Pharmatech AS (Fredrikstad, Norway), with
56 sealed plastic-coated aluminum bags per box. The boxes were marked with A or B, i.e., blinded for
both participants and personnel involved in this study. The intervention material contained 4 g of
hydrolyzed protein from cod (cuttings and trimmings) in addition to 5 g glucose hydrate (Cargill),
2 g maltodextrin, 0.025 g tastegram powder flavor, 0.7 g citric acid and 0.1 g lemongrass durarome
taste. The placebo contained 6.5 g of maltodextrin, 0.2 g citric acid, and was otherwise identical to
the active material. The active material could not be identified from the placebo according to flavor
or appearance.
The cod protein hydrolysate was produced by enzymatic hydrolysis of fresh frozen meat (cuttings
and trimmings) from Atlantic cod (Gadus morhua). A batch of 500 kg frozen raw material was grounded,
transferred to an incubator and mixed with sweet water at a ratio of 1:1, followed by stirring at 80 rpm
and heating to 55 ◦C. The enzyme preparation Protamex® (Novozymes AS, Copenhagen, Denmark)
was then added, following incubation for 45 min, at 55 ◦C and pH 7.0. The preparation (incubate) was
heated to 90 ◦C for 15 min to inactivate the enzyme. The enzyme-inactivated incubate was passed
through a rotating sieve (Swenco, Sweden) to remove any bone fragments. A two-phase centrifugation
(Alfa Laval AS, Denmark) was used to separate the peptide-containing water-soluble fraction (the
hydrolysate) from the indigested residue. This was followed by ultrafiltration and dehydration of the
soluble phase to a 50% dry matter concentrate, which was spray dried to a powder. The spray dried
CPH powder contained 89% crude protein, 0% carbohydrate, <0.2% fat, 0% carbohydrate, <3.0% water,
0.1% sodium chloride, 1.7% sodium, 0.07% chloride and 10% ash. Of the total amino acid content in the
hydrolysate, the free amino acids constituted 4.77%, and the ratio between essential amino acids and
non-essential amino acids was 0.70. When analyzing the molecular weight (MW) of the hydrolysate,
approximately 90% of the peptides present in the hydrolysate had a MW of 2000 Daltons (Da) or
less, which corresponds to peptides consisting of 18 amino acids or less. Furthermore, approximately
75% had a MW of 1000 Da or below, corresponding to 10 amino acids or less, and 55% had a MW of
500 Da, corresponding to 5 amino acids or less. Approximately 25–30% of the hydrolysate was small
dipeptides and free amino acids, with a MW of less than 200 Da. The composition of amino acids and
taurine content of the spray dried CPH powder are given in a previous publication [16].
2.6. Estimation of Energy and Macronutrient Intake
To determine individual diet habits, the participants recorded food and drink intake in a three-day
prospective food diary, including one weekend day, before the baseline visit and before the end of
study visit. Energy and protein intake from the supplement was added to the end of study dietary
records (CPH group: 44 kcal, 4 g protein; placebo group: 46.5 kcal, 0 g protein). We used dietary
records to evaluate whether any changes were made in the participants diets during the intervention
period and to record diet patterns. Calculations of energy and macronutrient intake were determined
using “Kostholdsplanleggeren” [27].
2.7. Analyses of Blood Samples
Samples for safety purposes (albumin, prealbumin, leucocytes, thrombocytes, hemoglobin, sodium,
potassium, alanine aminotransferase, alkaline phosphatase, creatinine and aspartate aminotransferase)
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were taken at the screening and end of study visit. Glycated hemoglobin (HbA1c), total-C, TAG,
LDL-C, HDL-C and fasting and postprandial serum insulin and glucose were measured at baseline
and end of study visit. All tests were analyzed according to standard accredited methods at the routine
hospital laboratories (Department of Medical Biochemistry and Pharmacology, HUH, and Department
of Medical Biochemistry, Ålesund Hospital).
Samples for GLP-1 determination were collected in Vacuette® EDTA-K2 tubes, ref#454047 (Greiner
Bio-One GmbH, Frickenhausen, Germany), with 20 µL dipeptidyl peptidase-4 inhibitor (DPP4-010; DRG
Diagnostics, Marburg, Germany) added prior to sampling. Plasma for fasting and postprandial GLP-1 at
baseline and end of study was obtained by centrifugation of EDTA blood at 1800× g and −4 ◦C for 10 min,
within 20 min after blood sampling. Plasma GLP-1 was analyzed by ELISA method (GLP-1, Active form
(High Sensitivity ELISA), Code No. 27700, (Immuno-Biological Laboratories Co., Ltd., IBL Japan)).
2.8. Randomization
To allocate the participants, we used a web-based data collection and randomization system
developed and administered by the Norwegian University of Science and Technology, Trondheim,
Norway. We used block randomization to create the random assignment order and stratified for center
(Ålesund or Bergen). A person with no practical involvement in the trial coded the test materials.
The participants, study investigator, and all other personnel involved in this study were blinded to
group allocation. Study investigators were given the key of randomization after the trial was finished
and the statistical analyses were carried out.
2.9. Statistical Analyses
We performed statistical analyses by IBM SPSS Statistics, Version 26.0 (IBM Corp., Armonk, NY,
USA) and GraphPad Prism version 8.4.1 (GraphPad Software, Inc., San Diego, CA, USA. The latter
was used for graphical work. The data is presented as the mean ± SD, unless otherwise stated.
Normality was evaluated by the Shapiro–Wilk test and histograms, and non-normally distributed data
was log-transformed before using parametric statistical tests. We tested changes within groups from
baseline to end of study by the paired sampled t-test, and changes between groups by the independent
samples t-test. We examined group differences over time for continuous outcome (postprandial
measurements of insulin, glucose and GLP-1) in a linear mixed-effects model with repeated measures.
The trapezoid rule was used when calculating the area under the curve (AUC) using only end of study
day, comparing the active and placebo group. Level of significance was set to p < 0.05. Two participants
in the placebo group were excluded from the statistical analysis of lipid parameters (TAG, total-C,
LDL-C and HDL-C), due to the use of lipid-lowering drugs (Simvastatin (Zocor), Atorvastatin).
To our knowledge, the possible effects of supplementation with a hydrolyzed cod protein have
not been investigated previously in overweight and obese subjects with MetS. Due to a lack of similar
studies, a power calculation was not performed. According to the protocol, we planned to recruit
60 participants in this study, with 30 participants in each group (a minimum of 20 in each group). This is
a number similar to what has been previously reported in studies with supplementation of low doses
of cod protein in humans [20,21]. We did not reach the target population due to difficulties with the
recruitment of eligible participants. Participants were recruited between April and September 2019, but
due to time constraints and limited resources, the inclusion of new participants had to stop in September.
3. Results
3.1. Participants
Of 58 participants attending the screening visit, 35 subjects had MetS and could be included in the
trial. Four participants withdrew before randomization. Thirty participants completed the intervention
according to study protocol and were included in the statistical analysis (Figure 1). At the screening
visit, the groups were comparable (Table 1).
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Mean SD Mean SD
Gender (female/male) 11/4 13/2 0.651
Age, years 52.8 6.26 53.4 6.83 0.804
Anthropometric measurements
Body weight, kg 96.5 12.8 93.4 12.2 0.509
WC, cm 107.6 9.72 105.7 10.7 0.630
BMI, kg/m2 32.7 2.24 32.4 3.25 0.751
Blood pressure (BP)
Systolic BP, mmHg 136.9 15.9 138.5 15.1 0.756
Diastolic BP, mmHg 88.2 10.1 86.7 6.44 0.702
Glucose metabolism
Glucose, mmol/L 5.73 0.75 5.63 0.79 0.704
HbA1c, mmol/mol 37.5 4.47 35.7 3.40 0.208
Lipid metabolism
Total cholesterol, mmol/L 5.8 1.1 5.5 0.8 0.466
HDL cholesterol, mmol/L 1.3 0.3 1.4 0.2 0.493
LDL cholesterol, mmol/L 4.2 0.1 3.9 0.8 0.334
Triacylglycerol, mmol/L 2.10 0.7 2.05 0.6 0.870
Numbers using BP medications 5 9 -
Tobacco users 1 2 -
SD, standard deviation; WC, waist circumference; BMI, body mass index BP, blood pressure; BW, body weight;
Hba1c, glycated hemoglobin. Results are presented as the mean ± SD. Groups were compared at baseline using
independent samples t-test for continuous data and Fisher’s Exact Test for categorical data.
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3.2. Estimated Intake of Energy and Macronutrient
The estimated intake of energy and macronutrients calculated from the dietary records did not
differ between the groups at baseline, and we did not observe any changes within or between groups
during the course of this study (Table 2).
Table 2. Estimated energy and macronutrient intake in the cod protein hydrolysate (CPH) group
(n = 15) and the placebo group (n = 15) at baseline and end of study (8 weeks).
Variable
Baseline 8 Weeks
p-Value 2 p-Value 3 p-Value 4
Mean SD Mean SD
Energy intake, kcal/day 0.668 0.726
CPH 1882 485 1777 466 0.177
Placebo 1812 386 1746 410 0.406
Protein, g/kg BW/day 0.922 0.815
CPH 0.91 0.22 0.85 0.24 0.357
Placebo 0.91 0.29 0.87 0.23 0.569
Fat, g/day 0.122 0.396
CPH 84.9 24.4 77.8 24.2 0.128
Placebo 71.9 20.2 70.2 24.99 0.723
Carbohydrate, g/day 0.323 0.488
CPH 193.2 46.0 191.7 51.3 0.848
Placebo 211.1 51.5 198.4 49.3 0.207
Basal metabolic rate1, kcal 0.579 0.743
CPH 1760 334 1774 350 0.211
Placebo 1696 296 1700 264 0.399
SD, standard deviation; BW, body weight. 1 Derived from the bioimpedance analysis. 2 p-values comparing groups
at baseline are based on independent samples t-test. 3 p-values within groups based on paired sample t-test. 4
p-values comparing change between groups are based on independent samples t-test. Data is based on the mean
values from a three-day dietary records. Energy and protein content from the supplement was added to the end of
study data—CPH group: 4 g protein, 44 kcal; placebo group: 0 g protein, 46.5 kcal. Results are presented as the
mean ± SD.
3.3. Anthropometric Measurements
Body weight (kg), fat mass (kg, %), fat-free mass (kg), BMI (kg/m2) or total body water (kg) did
not differ within or between the groups (Table 3). Waist circumference increased within both the CPH
group and the placebo group, but no differences were observed when comparing the two groups
(Table 3).
3.4. Glucose Homeostasis
Adjusted for time and visit, the glucose levels were on average 0.55 mmol/L higher for CPH
compared to placebo, but the linear mixed-effects model with repeated measures did not reveal any
significant differences between the groups (95% CI: (−0.44, 1.53), p = 0.267). We observed no change
in glucose levels from baseline visit to end of study visit in either of the two groups (overall change:
−0.014 mmol/L, 95% CI: (−0.19, 0.16), p = 0.876) (Figure 2a). Similarly, no difference in insulin levels
was observed between the two groups after 8 weeks intervention. The insulin levels were on average
0.63 mIU/L higher for CPH compared to placebo (95% CI: (−31.32, 32.58), p = 0.968), and we did
not observe any changes in insulin levels from baseline visit to end of study in either of the groups
(overall change: 0.57 mIU/L, 95% CI: (−4.79, 5.92), p = 0.836) (Figure 2c). Furthermore, no difference in
fasting or postprandial GLP-1 levels was observed between the two groups. The GLP-1 levels were on
average 0.83 pmol/L higher (back transformed estimate) for participants who received CPH compared
to placebo, but this was not significantly different (95% CI: (0.61, 1.13), p = 0.221). We did not observe
any changes in GLP-1 levels from baseline visit to end of study visit in either of the groups (overall
change: 0.95 pmol/L, 95% CI: (0.90, 1.01), p = 0.079) (Figure 2e).
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Table 3. Anthropometric measurements and results from the bioimpedance analysis (BIA) in the cod
protein hydrolysate (CPH) group (n = 15) and the placebo group (n = 15) at baseline and end of study
(8 weeks).
Variable
Baseline End of Study
p-Value2 p-Value3
Mean SD Mean SD
Body weight, kg 0.557
CPH 96.02 13.6 96.14 13.8 0.715
Placebo 93.15 12.7 92.93 12.2 0.694
BMI, kg/m2 0.603
CPH 32.55 2.43 32.59 2.51 0.741
Placebo 32.27 3.45 32.21 3.49 0.692
Waist circumference1 0.512
CPH 105.5 9.72 108.8 7.25 0.014
Placebo 105.9 10.7 108.2 9.49 0.040
Fat mass, % 0.897
CPH 39.91 6.79 39.50 7.12 0.211
Placebo 40.21 5.37 39.75 5.47 0.105
Fat mass, kg 0.834
CPH 38.16 7.81 37.82 8.12 0.319
Placebo 37.46 7.05 37.03 7.46 0.163
Fat-free mass, kg 0.816
CPH 57.81 11.54 58.33 12.01 0.221
Placebo 55.71 10.08 55.92 9.02 0.301
Total body water, kg 0.325
CPH 42.39 8.47 42.45 8.89 0.974
Placebo 41.29 7.34 40.64 6.77 0.322
SD, standard deviation; BMI, body mass index. 1 For waist circumference, the results are data measured at the
screening visit, and presented for only n = 13 in the CPH group and n = 14 in the placebo group due to missing
values. 2 P-values within groups are based on paired samples t-test. 3 P-values comparing change between groups
are based on independent samples t-test.
We observed no significant interactions between group and visit (baseline vs. end of study), group
and time, time and visit or between group, visit and time for insulin, glucose or GLP-1. The AUC
calculated from the fasting through the postprandial test points did not reveal any significant differences
in insulin, glucose or GLP-1 levels between the CPH group and placebo group after 8 weeks (Figure 2b,
d and f, respectively).
At baseline, HbA1c was on average 37.5 ± 4.47 mmol/mol in the CPH group and
35.7 ± 3.40 mmol/mol in the placebo group, with no differences between groups (mean diff: 1.87,
95% CI: (−1.102, 4.835), p = 0.208). HbA1c did not change during the supplementation period within
the CPH group (mean diff: 0.40 mmol/mol, 95% CI: (−1.15, 1.95), p = 0.589) or the placebo group (mean
diff: 0.00, 95% CI: (−1.24, 1.24), p = 1), and there was no difference between the groups (mean difference:
0.40, 95% CI: (−1.49, 2.29), p = 0.669).
3.5. Lipid Parameters
At baseline, no differences between the groups were observed for fasting TAG, HDL-C, LDL-C,
total-C or total-C: HDL-C ratio. Fasting total-C and LDL-C were significantly decreased within both
groups after 8 weeks of intervention, with no differences between the groups (Figure 3). Fasting TAG
was reduced within the CPH group (mean diff: −0.81 mmol/L (back transformed estimate), 95% CI:
(0.694, 0.948), p = 0.012), but did not differ from placebo (Figure 3). We did not observe any changes
within or between groups for for fasting HDL-C and total-C: HDL-C ratio during the course of the
study (Figure 3).
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Figure 3. Fasting and change in serum levels of triacylglycerol (TAG) (a,b), total cholesterol (total-C)
(c,d), high-density lipoprotein cholesterol (HDL-C) (e,f) and low-density lipoprotein cholesterol (LDL-C)
(g,h) in subjects with MetS after 8 weeks intervention with cod protein hydrolysate (CPH) (n = 15) or
placebo (n = 13). Two subjects from the placebo group were excluded from the statistical analyses of
lipid parameter due to the use of lipid-lowering drugs. A (c,e,g), results are presented as individual
graphs with fasting levels at baseline and end of study for each subject, with bars showing the mean in
each group. p-values were calculated from a paired samples t-test. B (d,f,h), changes were calculated as
individual end of study values minus baseline values for each of the indicators. Results are presented
as the mean difference. p-values were calculated using the independent samples t-test. Significant
p-values are marked with asterisk (*).
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3.6. Adverse Effects
Biochemistry for safety purposes were all within normal range. Seven participants reported
discomfort during the intervention period—four in the CPH group and three in the placebo group.
One participant in the CPH group reported that the supplement tasted bad and caused retching.
Two participants in the CPH group reported heartburn, and two reported nausea at the beginning of
the intervention period, but this was transient. In the placebo group, one participant reported myalgia,
one reported itchy rash in the face and one reported nausea, but all three participants were unsure
whether these experiences were related to the intervention.
4. Discussion
The main aim of this study was to investigate whether daily supplementation with low doses of
CPH for 8 weeks would have effect on fasting and postprandial glucose levels in participants with
MetS. We hypothesized that supplementation with CPH would lead to beneficial changes in glucose
metabolism and an overall healthier metabolic profile. We did not observe any significant effects of
the supplement on the primary outcome measure (fasting and postprandial glucose levels) when
compared to placebo. Furthermore, we found no effect on fasting or postprandial insulin or GLP-1
levels, lipid parameters or body composition after 8 weeks supplementation with CPH.
Previous human intervention studies have reported improvements in postprandial glucose and
insulin levels after supplementation with fish protein [20,28], and similar findings have been observed
in animal studies [14,29,30]. Furthermore, we have previously shown that the postprandial insulin
concentration in serum was significantly lower in normal-weight adults given one single dose of CPH
compared to control (unhydrolyzed casein), without an effect on glucose levels [31]. Considering
that the subjects in the current trial had MetS, the lack of effect is surprising, but there could be
several reasons for this. Firstly, we gave the participants a fixed dose of 4 g of CPH, whereas we used
weight-adjusted doses of CPH in previous studies, to reduce the effect of body weight variations [16,31].
In the current trial, the participants in the CPH group had a body weight ranging from 77 to 133 kg,
meaning variation from 52 to 30 mg/kg body weight of CPH per day, which could possibly affect the
overall results. It was not feasible to weight-adjust the doses in the current trial, and we therefore
chose to use a fixed dose similar to what has been used in other studies and based on results from a
previous study conducted by our research group [20,21,31]. Secondly, the participants in the current
trial only received a daily morning dose of CPH. Previous studies have suggested that distributing
the doses throughout the day might lead to a more potent effect due to a constant flow of bioactive
peptides in circulation [32,33].
The estimated average daily protein intake for participants in the CPH group was 85 g/day, and
only 4.7% of the total daily protein intake came from the supplement. Therefore, we do not presume
the protein intake as such to cause any effect on postprandial glucose regulation and lipid profile. We
believe that an effect may be due to particular peptide sequences in the supplement. Bioactive peptide
sequences have been identified in other fish protein hydrolysates [34]. We did not test for the presence
of such sequences in this particular study, which would have strengthened the design.
Dietary proteins play a role in the regulation of lipid metabolism, and beyond the quantity of
protein, the composition of amino acids and bioactive peptides are suggested to be of importance [35].
Associations between a high intake of lean fish and reduced levels of serum TAG [5,8], as well as
increased levels of HDL-C [8], have been reported in previous cross-sectional studies. Beneficial effects
have also been reported from intervention studies in animals and humans [36–38]. In the current trial,
we observed a significant reduction in serum fasting TAG levels in the CPH group, with a decline of
18% from baseline to end of study. Considering that a weight reduction of 5–10% has been shown to
cause a 20–30% reduction in TAG levels, whereas general improvement of nutrition-related practices
can lead to a TAG-lowering effect of between 20 and 50% [39], a reduction of 18% in TAG levels after
8 weeks of supplementation with CPH, with no change in body weight or composition, is interesting.
However, these changes did not differ from the placebo group, hence the results should be interpreted
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with caution. In line with findings from previous intervention studies with low doses of cod protein in
healthy, overweight adults [20] and normal-weight adults [33], we observed reduced levels of LDL-C
within the CPH group. However, a reduction in LDL-C was also observed within the placebo group,
and no differences were found when comparing the two groups. Overall, we did not observe any
effects of 8 weeks CPH supplementation on lipid parameters.
Proteins are considered to be the most satiating of the macronutrients [40], and there are indications
that fish protein, compared to other animal proteins like beef and chicken, have a greater effect on
satiety [41]. The gut hormone, GLP-1, released in response to intake of food from the enteroendocrine L
cells, is involved in appetite regulation and contributes to glycemic control by slowing gastric emptying,
stimulating insulin secretion and suppressing the secretion of glucagon [42–44]. A previous study
in overweight individuals found increased levels of GLP-1 after 3 months supplementation with 1.4
and 2.8 g of blue whiting hydrolysate, when compared to placebo (whey protein isolate) [17]. In the
current trial, we did not see any effect of supplementation with 4 g of CPH for 8 weeks on fasting
or postprandial GLP-1 levels. In the trial by Nobile et al. [17], all groups had a caloric restriction of
−300 kcal per day, which may have influenced the result and might suggest that a reduction in calories
in combination with supplementation of fish protein hydrolysate is a more effective approach than
supplementation alone.
There are some limitations to the present study. Firstly, the lack of a power analysis and the
small number of subjects per group might explain why we were not able to observe any effect of the
intervention. Secondly, we did not reach the target population according to protocol, due to difficulties
with recruiting eligible subjects and strict inclusion and exclusion criteria. We had to stop the inclusion
period due to time constraints and limited resources, and the low number of subjects might have
compromised this study. By choosing a cross-over design, we could have recruited fewer subjects and
strengthened the design. This was not done in the current trial due to the long intervention period,
which would require at least 4 weeks wash-out period in between the two experimental periods and the
possibility of a high drop-out rate. Furthermore, participating in an intervention study may influence
eating patterns and lead to underreporting of dietary intake. We instructed the participants to continue
eating and activity level as normal during the course of this study, and we did not observe any changes
in dietary intake or body weight. However, the estimated energy intake from the diet diaries were
lower than anticipated according to weight. It should also be mentioned that body composition was
assessed with BIA, which is suggested to be effective in healthy individuals and individuals with a
stable water and electrolyte balance. The results should be interpreted with caution in individuals with
BMI >34 kg/m2 [45], and overestimating of fat-free mass has been observed when using BIA compared
to dual-energy x-ray absorptiometry in obese subjects with BMI >35 kg/m2 [46]. Since the average BMI
in the current study was 32.5 kg/m2, we assume that the results from the BIA analysis are reliable.
No previous publication, to our knowledge, has investigated supplementation with a low dose
of a hydrolysate from cod in a population with MetS. To conclude, in this study, we showed that
consumption of 4 g of a CPH daily for 8 weeks in individuals with MetS had no effect on fasting or
postprandial glucose, insulin levels or GLP-1 levels, lipid profile or body composition. Studies in the
future should further evaluate the effect of fish protein hydrolysate on lipid regulation, and preferably
with a larger group of participants over a longer time period. Furthermore, the presence of potential
bioactive peptide sequences with antidiabetic or lipid-lowering effects in the cod protein hydrolysate
and the potential mechanism of effect should be explored further.
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